Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | CTSH | P09668 | 1/20 | 0.53 |
| ▸ | GLP1R | P43220 | 5/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.51 |
| ▸ | GRPR | P30550 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183034 | 0.97 | GLP1R (0.55) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL29489380 | 0.94 | CTSL (0.53) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30064553 | 0.94 | GLP1R (0.58) | GLP1RIL23RGRPR | |
| SCHEMBL30338573 | 0.94 | GLP1R (0.54) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30932143 | 0.93 | GLP1R (0.60) | GLP1RCXCR4KEAP1 | |
| SCHEMBL29670477 | 0.93 | NPBWR1 (0.56) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL30208638 | 0.92 | GLP1R (0.57) | GLP1RCXCR4IL23R | |
| SCHEMBL29774221 | 0.92 | IL23R (0.50) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL29613390 | 0.92 | IL23R (0.55) | CTSLCTSSCTSKCTSHGLP1R | |
| SCHEMBL29434537 | 0.92 | GLP1R (0.57) | GLP1RIL23RGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4585228-A2 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-12290566-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-20240285725-A1 | DOSING REGIMENS | SIXTH STREET LENDING PARTNERS | 2024-08-29 | — | — | US | disclosed |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2024-04-11 | — | — | US | disclosed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | disclosed |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | SIXTH STREET LENDING PARTNERS | 2023-03-23 | — | — | US | disclosed |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3660033-B9 | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | CTSL 428/4885CTSS 943/4885CTSK 876/4885 |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | CTSL 33/4885CTSS 106/4885CTSK 182/4885 |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | C3AR1, C5AR1, SERPINC1 | CTSL 10/4885CTSS 56/4885CTSK 61/4885 |
| US-20230009757-A1 | COMBINATION THERAPY FOR C3 INHIBITION | C3AR1, C5, CFH | CTSL 43/4885CTSS 178/4885CTSK 209/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | CTSL 33/4885CTSS 106/4885CTSK 182/4885 |
| US-12290566-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | CTSL 33/4885CTSS 106/4885CTSK 182/4885 |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | CTSL 33/4885CTSS 106/4885CTSK 182/4885 |
| US-20240285725-A1 | DOSING REGIMENS | C3AR1, C1QBP, C9 | CTSL 21/4885CTSS 72/4885CTSK 118/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | CTSL 10/4885CTSS 56/4885CTSK 61/4885 |
| US-20240115655-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | CTSL 33/4885CTSS 106/4885CTSK 182/4885 |
| US-20230091471-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | CTSL 16/4885CTSS 50/4885CTSK 75/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | CTSL 18/4885CTSS 194/4885CTSK 241/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | CTSL 56/4885CTSS 107/4885CTSK 287/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | CTSL 43/4885CTSS 178/4885CTSK 209/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | CTSL 7/4885CTSS 58/4885CTSK 147/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | CTSL 10/4885CTSS 100/4885CTSK 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.